Literature DB >> 27809929

Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling.

Sunil S Adav1, Siu Kwan Sze2.   

Abstract

Dementia is a syndrome associated with a wide range of clinical features including progressive cognitive decline and patient inability to self-care. Due to rapidly increasing prevalence in aging society, dementia now confers a major economic, social, and healthcare burden throughout the world, and has therefore been identified as a public health priority by the World Health Organization. Previous studies have established dementia as a 'proteinopathy' caused by detrimental changes in brain protein structure and function that promote misfolding, aggregation, and deposition as insoluble amyloid plaques. Despite clear evidence that pathological cognitive decline is associated with degenerative protein modifications (DPMs) arising from spontaneous chemical modifications to amino acid side chains, the molecular mechanisms that promote brain DPMs formation remain poorly understood. However, the technical challenges associated with DPM analysis have recently become tractable due to powerful new proteomic techniques that facilitate detailed analysis of brain tissue damage over time. Recent studies have identified that neurodegenerative diseases are associated with the dysregulation of critical repair enzymes, as well as the misfolding, aggregation and accumulation of modified brain proteins. Future studies will further elucidate the mechanisms underlying dementia pathogenesis via the quantitative profiling of the human brain proteome and associated DPMs in distinct phases and subtypes of disease. This review summarizes recent developments in quantitative proteomic technologies, describes how these techniques have been applied to the study of dementia-linked changes in brain protein structure and function, and briefly outlines how these findings might be translated into novel clinical applications for dementia patients. In this review, only spontaneous protein modifications such as deamidation, oxidation, nitration glycation and carbamylation are reviewed and discussed.

Entities:  

Keywords:  Alzheimer disease; Biomarkers; Deamidation; Degenerative protein modifications (DPMs); Dementia; Neurodegenerative disease; Nitration; Oxidation; β-amyloid

Mesh:

Substances:

Year:  2016        PMID: 27809929      PMCID: PMC5094070          DOI: 10.1186/s13041-016-0272-9

Source DB:  PubMed          Journal:  Mol Brain        ISSN: 1756-6606            Impact factor:   4.041


  227 in total

Review 1.  The genetics of the amyloidoses.

Authors:  J N Buxbaum; C E Tagoe
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

Review 2.  Glucose metabolism in the developing brain.

Authors:  R C Vannucci; S J Vannucci
Journal:  Semin Perinatol       Date:  2000-04       Impact factor: 3.300

3.  Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo.

Authors:  C N Bassett; M D Neely; K R Sidell; W R Markesbery; L L Swift; T J Montine
Journal:  Lipids       Date:  1999-12       Impact factor: 1.880

4.  The number of trait loci in late-onset Alzheimer disease.

Authors:  E W Daw; H Payami; E J Nemens; D Nochlin; T D Bird; G D Schellenberg; E M Wijsman
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

5.  Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library.

Authors:  G Münch; D Schicktanz; A Behme; M Gerlach; P Riederer; D Palm; R Schinzel
Journal:  Nat Biotechnol       Date:  1999-10       Impact factor: 54.908

6.  Alzheimer neuropathologic alterations in aged cognitively normal subjects.

Authors:  D G Davis; F A Schmitt; D R Wekstein; W R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  1999-04       Impact factor: 3.685

7.  mGluR7-like metabotropic glutamate receptors inhibit NMDA-mediated excitotoxicity in cultured mouse cerebellar granule neurons.

Authors:  M Lafon-Cazal; L Fagni; M J Guiraud; S Mary; M Lerner-Natoli; J P Pin; R Shigemoto; J Bockaert
Journal:  Eur J Neurosci       Date:  1999-02       Impact factor: 3.386

8.  Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.

Authors:  A Lobo; L J Launer; L Fratiglioni; K Andersen; A Di Carlo; M M Breteler; J R Copeland; J F Dartigues; C Jagger; J Martinez-Lage; H Soininen; A Hofman
Journal:  Neurology       Date:  2000       Impact factor: 9.910

9.  Increased lipoprotein oxidation in Alzheimer's disease.

Authors:  S Schippling; A Kontush; S Arlt; C Buhmann; H J Stürenburg; U Mann; T Müller-Thomsen; U Beisiegel
Journal:  Free Radic Biol Med       Date:  2000-02-01       Impact factor: 7.376

Review 10.  The role of cerebral ischemia in Alzheimer's disease.

Authors:  R N Kalaria
Journal:  Neurobiol Aging       Date:  2000 Mar-Apr       Impact factor: 4.673

View more
  13 in total

Review 1.  Metabolomics Signatures of Aging: Recent Advances.

Authors:  Sunil S Adav; Yulan Wang
Journal:  Aging Dis       Date:  2021-04-01       Impact factor: 6.745

Review 2.  The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer's disease.

Authors:  Yan-Li Zhang; Juan Wang; Zhi-Na Zhang; Qiang Su; Jun-Hong Guo
Journal:  Neural Regen Res       Date:  2022-11       Impact factor: 6.058

3.  Commentary: Immunochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases.

Authors:  Ian Paul Johnson; Cintia Roodveldt
Journal:  Front Neurol       Date:  2017-03-20       Impact factor: 4.003

4.  Lactuca capensis reverses memory deficits in Aβ1-42-induced an animal model of Alzheimer's disease.

Authors:  Paula Alexandra Postu; Jaures A K Noumedem; Oana Cioanca; Monica Hancianu; Marius Mihasan; Mitica Ciorpac; Dragos Lucian Gorgan; Brindusa Alina Petre; Lucian Hritcu
Journal:  J Cell Mol Med       Date:  2017-08-16       Impact factor: 5.310

Review 5.  Alzheimer's disease: pathogenesis, diagnostics, and therapeutics.

Authors:  Sneham Tiwari; Venkata Atluri; Ajeet Kaushik; Adriana Yndart; Madhavan Nair
Journal:  Int J Nanomedicine       Date:  2019-07-19

6.  Platelet phosphorylated TDP-43: an exploratory study for a peripheral surrogate biomarker development for Alzheimer's disease.

Authors:  Rodger Wilhite; Jessica M Sage; Abdurrahman Bouzid; Tyler Primavera; Abdulbaki Agbas
Journal:  Future Sci OA       Date:  2017-08-16

7.  Brain ureido degenerative protein modifications are associated with neuroinflammation and proteinopathy in Alzheimer's disease with cerebrovascular disease.

Authors:  Xavier Gallart-Palau; Aida Serra; Benjamin Sian Teck Lee; Xue Guo; Siu Kwan Sze
Journal:  J Neuroinflammation       Date:  2017-09-02       Impact factor: 8.322

8.  Monocyte adhesion to atherosclerotic matrix proteins is enhanced by Asn-Gly-Arg deamidation.

Authors:  Bamaprasad Dutta; Jung Eun Park; Subodh Kumar; Piliang Hao; Xavier Gallart-Palau; Aida Serra; Yan Ren; Vitaly Sorokin; Chuen Neng Lee; Hee Hwa Ho; Dominique de Kleijn; Siu Kwan Sze
Journal:  Sci Rep       Date:  2017-07-18       Impact factor: 4.379

Review 9.  Origin and pathophysiology of protein carbonylation, nitration and chlorination in age-related brain diseases and aging.

Authors:  Efstathios S Gonos; Marianna Kapetanou; Jolanta Sereikaite; Grzegorz Bartosz; Katarzyna Naparło; Michalina Grzesik; Izabela Sadowska-Bartosz
Journal:  Aging (Albany NY)       Date:  2018-05-17       Impact factor: 5.682

10.  Serum albumin cysteine trioxidation is a potential oxidative stress biomarker of type 2 diabetes mellitus.

Authors:  Selvam Paramasivan; Sunil S Adav; SoFong Cam Ngan; Rinkoo Dalan; Melvin Khee-Shing Leow; Hee Hwa Ho; Siu Kwan Sze
Journal:  Sci Rep       Date:  2020-04-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.